Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have updated their outlooks on several major stocks, including price target changes and rating adjustments. Notable changes include Stifel cutting Spire Global's price target, Oppenheimer boosting Analog Devices' target, and Goldman Sachs cutting Sagimet Biosciences' target. Other companies affected include Fate Therapeutics, Accenture, Zebra Technologies, Portland General Electric, Alibaba, monday.com, and Occidental Petroleum.
May 16, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. slashed the price target for Fate Therapeutics from $7 to $5, maintaining a Neutral rating. Shares gained 0.5% to $4.24.
The significant price target cut and neutral rating suggest a negative short-term outlook.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Truist Securities cut the price target for Occidental Petroleum from $84 to $69 and downgraded the stock from Buy to Hold. Shares climbed 0.5% to $63.38.
The price target cut and downgrade suggest a negative short-term outlook despite the slight share price increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Stifel cut the price target for Spire Global from $24 to $20 while maintaining a Buy rating. Shares fell 6.8% to $11.34.
The significant price target cut and the subsequent drop in share price indicate a negative short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Baird cut the price target for Accenture from $372 to $345, maintaining a Neutral rating. Shares gained 0.5% to $308.52.
The price target cut and neutral rating suggest a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Mizuho raised the price target for Portland General Electric from $42 to $45, maintaining a Neutral rating. Shares rose 0.8% to $44.64.
The price target increase and neutral rating suggest a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Goldman Sachs cut the price target for Sagimet Biosciences from $27 to $23 while maintaining a Buy rating. Shares rose 5.5% to $4.62.
Despite the price target cut, the Buy rating and share price increase suggest a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Oppenheimer boosted the price target for Analog Devices from $215 to $245, maintaining an Outperform rating. Shares rose 1.8% to $215.75.
The increased price target and positive rating suggest a favorable short-term outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
B of A Securities raised the price target for Alibaba from $99 to $103, maintaining a Buy rating. Shares gained 1.9% to $80.99.
The increased price target and positive rating suggest a favorable short-term outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Keybanc raised the price target for monday.com from $275 to $280, maintaining an Overweight rating. Shares jumped 21.4% to $220.72.
The increased price target and significant share price jump suggest a highly favorable short-term outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Needham boosted the price target for Zebra Technologies from $352 to $370, maintaining a Buy rating. Shares rose 0.9% to $323.87.
The increased price target and positive rating suggest a favorable short-term outlook.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70